

Tolerability and Safety of Lasmiditan Treatment in Elderly Analyses From Randomized Studies

Clinical Therapeutics

43, 1066-1078

DOI: [10.1016/j.clinthera.2021.04.004](https://doi.org/10.1016/j.clinthera.2021.04.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab. Pharmaceuticals, 2021, 14, 924.	3.8	5
2	Cardiovascular Disease and Migraine: Are the New Treatments Safe?. Current Pain and Headache Reports, 0, , .	2.9	7
3	New Oral Drugs for Migraine. CNS Drugs, 2022, 36, 933-949.	5.9	11
4	Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. Cephalalgia, 2023, 43, 033310242211370.	3.9	8
5	New Migraine Drugs for Older Adults. Drugs and Aging, 2023, 40, 301-305.	2.7	0
6	Research Progress of Emerging Therapeutic Drugs in the Acute Onset Period of Migraine. Advances in Clinical Medicine, 2023, 13, 7700-7706.	0.0	0
7	Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Devepment, and Place in Therapy. Drug Design, Development and Therapy, 0, Volume 17, 1979-1993.	4.3	0
8	The 5-HT1F receptor as the target of ditans in migraine â€” from bench to bedside. Nature Reviews Neurology, 0, , .	10.1	0
9	The history and rationale of the development of new drugs for migraine treatment. Arquivos De Neuro-Psiquiatria, 2023, 81, 1084-1097.	0.8	1
10	The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review. Pain and Therapy, 0, , .	3.2	0